VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Location: United States, New Jersey, Bridgewater
Employees: 51-200
Founded date: 2003
Investors 3
| Date | Name | Website |
| 27.11.2023 | Access Bio... | accessbio-... |
| - | Perceptive... | perceptive... |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 5
| Date | Title | Description |
| 19.01.2022 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | Item 8.01 Other Events. On January 19, 2022, VYNE Therapeutics Inc. (the "Company") issued a press release entitled "VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Mod... |
| 21.10.2021 | VYNE Therapeutics : Announces Formation of Scientific Advisory Board | Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NE... |
| 30.03.2021 | VYNE THERAPEUTICS INC. VYNE Therapeutics : Investor Relations Presentation | INVESTOR PRESENTATION March 2021 Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding... |
| 07.10.2020 | VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts | |
| 01.10.2020 | VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st |